The dedicated cardiovascular outcomes trial TRIUMPH-Outcomes, enrolling ~10,000 participants over roughly 5 years is the study designed and powered to answer the cardiovascular benefit question definitively

GLP-1 Receptor Activation This is the same pathway used by Semaglutide (Ozempic, Wegovy): Suppresses appetite via hypothalamic signaling Delays gastric emptying , prolonging fullness Improves insulin secretion and glucose control Lowers postprandial glucose and insulin resistance GIP Receptor Activation Shared with Tirzepatide, GIP provides several synergistic effects: Enhances insulin release in response to meals May reduce GI side effects (like nausea) seen with GLP-1s alone Potentially improves lipid metabolism and adipose tissue response Glucagon Receptor Activation This is where Retatrutide takes a leap beyond dual agonists: Increases energy expenditure and fat oxidation Mobilizes stored fat through hepatic lipolysis May preserve or enhance lean mass during weight loss Supports brown fat activation and thermogenesis The addition of glucagon receptor activation to GLP-1 and GIP may enhance fat oxidation and energy burn beyond whats seen with dual agonists. Coskun et al., Cell Metabolism Together, these pathways work synergistically: GLP-1 blunts hunger , GIP improves insulin dynamics , and glucagon turns up fat-burning efficiency

Gastroparesis: The Most Common Ozempic Injury Stomach paralysis (medically termed gastroparesis) represents the most frequently reported severe injury among patients taking GLP-1 medications
How Widespread Is Mycotoxin Exposure
However, challenges persist, particularly concerning the cost of these medications
The compounds in cannabis, like THC and CBD, can attach to receptors in this system and potentially influence these bodily functions